RxDoctor Payments DataLook up a doctor →

Raquel Volney, MD

Family Medicine · Middleboro, MANPI 1679663199

Payments from drug & device makers

$7,368in general payments, 2019–2025

Across 400 payments — averaging $18.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Pfizer$1K
  • Novo Nordisk$946
  • AstraZeneca$658
  • GSK$540
  • Johnson & Johnson$271
  • plus $3K from 39 others

What the payments were for

  • Food & beverage$7,28399%
  • Education$851%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,368 in reported general payments places this provider in the 95th percentile of 1,049 family medicine providers in Massachusetts.

See all family medicine providers in Massachusetts

Medicare billing

Part B allowed, 2024
$103,608
Medicare patients
287
Services billed
1,032

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban67$67,901
TrulicityDulaglutide30$36,463
JardianceEmpagliflozin18$27,005
Trelegy ElliptaFluticasone/Umeclidin/Vilanter29$23,913
XareltoRivaroxaban24$23,608
OzempicSemaglutide15$17,837
JanuviaSitagliptin Phosphate12$17,203
OxycontinOxycodone Hcl26$11,775
Breo ElliptaFluticasone/Vilanterol17$11,743
MyrbetriqMirabegron14$8,442
MovantikNaloxegol Oxalate16$6,071
Atorvastatin Calcium443$5,426
Albuterol Sulfate HfaAlbuterol Sulfate146$3,889
Gabapentin170$3,822
Levothyroxine Sodium365$3,821

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$1,005$67,90167 claims
Lilly USA, LLCTrulicity, Olanzapine$235$37,56375 claims
GSKTrelegy Ellipta, Breo Ellipta$540$35,65746 claims
Boehringer IngelheimJardiance$257$27,00518 claims
Johnson & JohnsonXarelto$271$23,60824 claims
Novo NordiskOzempic$946$17,83715 claims
Astellas Pharma US IncMyrbetriq$179$8,44214 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,049 family medicine providers in Massachusetts.

Other family medicine in Middleboro

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →